Mitsuhashi Atsushi, Okuma Yusuke, Zenke Yoshitaka, Hosomi Yukio
Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Tokyo 113-8677, Japan.
Division of Oncology, Research Center for Medical Sciences, Jikei University School of Medicine, Minato-ku, Tokyo 105-8461, Japan.
Mol Clin Oncol. 2018 Nov;9(5):561-565. doi: 10.3892/mco.2018.1710. Epub 2018 Sep 4.
Bone metastases (BM) often induce skeletal-related events (SREs) and contribute to poor prognoses in patients with cancer. Osteoclast inhibitors (OIs), such as bisphosphonates (BPs) and denosumab, reportedly prevent SREs and improve quality of life in patients with non-small cell lung cancer and BM, but have not been tested in extensive stage small cell lung cancer (ES-SCLC) patients. From 238 SCLC patient records, the present study reviewed those of 58 BM patients, including 23 who were treated with OIs (OIs group) and 35 who were untreated (untreated group). Patient backgrounds were balanced between groups using propensity score matching, and survival curves were compared using the log-rank test. The median overall survival (OS) times were 8.41 and 12.52 months in untreated and OIs groups, respectively, but these did not differ significantly between groups (log-rank test, P=0.409). The 1-year OS rate was higher in the OIs group (56.1%) when compared with the control group (22.6%). The results indicated that OIs tend to prolong the short term survival of ES-SCLC patients with BM. To the best of our knowledge, this is the first study to examine the prognostic effects of OIs in SCLC patients. The results of the present study may highlight the possibility that OIs improve the prognosis of ES-SCLC patients with BM.
骨转移（BM）常引发骨相关事件（SREs），并导致癌症患者预后不良。据报道，破骨细胞抑制剂（OIs），如双膦酸盐（BPs）和地诺单抗，可预防SREs并改善非小细胞肺癌和BM患者的生活质量，但尚未在广泛期小细胞肺癌（ES-SCLC）患者中进行测试。本研究从238例SCLC患者记录中回顾了58例BM患者的记录，其中23例接受了OIs治疗（OIs组），35例未接受治疗（未治疗组）。使用倾向评分匹配使两组患者背景均衡，并使用对数秩检验比较生存曲线。未治疗组和OIs组的中位总生存期（OS）分别为8.41个月和12.52个月，但两组之间无显著差异（对数秩检验，P=0.409）。与对照组（22.6%）相比，OIs组的1年OS率更高（56.1%）。结果表明，OIs倾向于延长ES-SCLC伴BM患者的短期生存期。据我们所知，这是第一项研究OIs对SCLC患者预后影响的研究。本研究结果可能凸显了OIs改善ES-SCLC伴BM患者预后的可能性。
